Search Results for : funding

Just two months until application submission – FDA Office of Orphan Products Development Natural History Studies grant funding opportunity

The grant application submission deadline is coming up in just 2 months! The application submission deadline for this grant funding opportunity is February 13, 2024.  Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) The purpose of this grant is to support efficient and innovative natural history studies that advance medical product development in rare […]

FDA Office of Orphan Products Development: Natural History Studies grant funding opportunity

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) announces the availability of funds for fiscal year (FY) 2024 to support natural history studies for rare diseases and conditions. This funding opportunity is intended to support prospective or retrospective, efficient, and innovative natural history studies with a focus on collaborative and standardized approaches to […]

New funding opportunity from NIH: IND-enabling Studies for Platform Clinical Trials of Genome Editing in Multiple Diseases

The US National Institutes of Health (NIH) published a new Notice of Funding Opportunity (NOFO) with the aim to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) for two or more disease indications, using the same genome editor, route of administration, and […]

Announcement of upcoming FDA Office of Orphan Products Development Natural History Studies grant funding opportunity

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal year (FY) 2024 to support natural history studies for rare diseases and conditions. This funding opportunity is intended to support prospective or retrospective, efficient, and innovative natural history studies with a focus on collaborative […]

FDA – Announcement of a Grant Funding Opportunity for Rare Disease Research

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a new […]

FDA: Announcement of New Grant Funding Opportunity for Rare Disease Research

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – FY 2025 to support clinical trials for rare diseases and conditions.  The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a […]

Announcement of New Grant Funding Opportunity for Rare Disease Research

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – FY 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in […]

Notice of Upcoming Funding Opportunity: National Pediatric Rare Disease Clinical Trials and Treatment Network

The Canadian Institute of Health Research – Institute of Genetics is pleased to announce the upcoming funding opportunity “National Pediatric Rare Disease Clinical Trials and Treatment Network”. The specific objectives of this funding opportunity are to: Develop a platform to support pediatric rare disease clinical trials in Canada; Increase the capacity to perform rare disease […]

Funding Models to Support the Spectrum of Rare Disease Research and Development

Introduction   The successful development of therapies for any disease requires support from early stages (basic/fundamental research), through more mature preclinical, translational, or early clinical stages, then more mature clinical stages, and finally, post-marketing studies. How different funders decide when to fund at a given stage in a treatment’s development is fairly opaque. Knowledge of the […]